The global stem cells market size was valued at USD 37.88 billion in 2013 and is expected to grow at a CAGR of over 20.0% up to 2020. Rising R&D initiatives to develop therapeutic options for chronic diseases and growing demand as regenerative treatment option are the most significant drivers of this industry. High unmet medical needs have led to more government initiatives for drug development and discovery.
According to the WHO report, cancer is the leading cause of mortality and morbidity worldwide. There were approximately 14 million new cancer cases and 8.2 million cancer-related deaths in 2012, and the cases are expected to reach around 22 million within the next two decades.
Stem cells therapy is classified under orphan drugs by the government with a view that when these are used with gene therapy, they can be used for the treatment of many intractable diseases.
The National Institute of Health had funded approximately USD 1.3 million in 2013. According to the 2014 update by the California’s Stem cells Agency, around USD 1.4 billion has been spent and USD 872 million is yet to be awarded for the research.
North America stem cellss market, by product, 2012-2020 (USD Million)
Product segments include adult stem cells, human embryonic, induced pluripotent stem, and natural rosette. Out of these, adult cellss dominated the industry and were valued around USD 32,558.9 million in 2013.
This is attributed to the low contamination probability at the time of expansion and sub-culture, better acceptance by human body, and relatively low production labor associated. However, induced pluripotent stem cells market is the fastest growing product and is projected to grow at a CAGR of over 25% due to its analogous nature of origin.
Key technologies are cells production, acquisition, cryopreservation, sub-culture, and expansion. Acquisition was the largest technology segment with revenue valued at USD 4,320.5 million in 2013. Large market share was due to the fact that it acts as a basic step in any of the techniques for acquiring stem cellss. The production segment is projected to grow at a rapid CAGR of over 12.0% over the next six years due to the increasing R&D initiatives in this segment.
Stem cellss are widely used in drug discovery and medicine and in regenerative medicine. In 2013, approximately 90% of the revenue was generated from regenerative medicine owing to the large unmet medical needs, regenerative medicines used in the chronic disease treatment of Parkinson’s and Huntington’s.
North America was the largest market owing to growing acceptance of therapies in this region along with the huge government funding for research and development and various initiatives in this region.
The Europe stem cells market was valued at around USD 10,129.0 million in 2013, and is projected to rise due to increasing government initiatives and R&D activities in this region. However, Asia Pacific region is expected to grow at a rapid rate due to rising contract research outsourcing and demand for medical tourism.
Market Share Insights
cellsartisAB, BioTime Inc., Advanced cells Technology Inc., cellsular Engineering Technologies Inc., and International Stem cells Corporation dominate the global stem cells market share. The industry players are involved in research activities in order to come up with new solutions and products to gain revenue share and sustainability.
Government initiatives to make researches more flexible, funds raised for regenerative medicines, and the key player strategies to collaborate, and launch or expansion new products in developing countries are expected to upsurge the industry over the forecast period.
In June 2015, cellsartis AB announced that it will be launching a culture, cellsartis EF-CS, used for the expansion of Induced Pluripotent Stem cellss (iPS). This advanced medium is Xeno-free and suitable for clinical and pre-clinical developments due to its rigorous compliance with the safety guidelines. The company was selected by the U.S. National Stem cells Bank to share its lines so that it could be available to the research community worldwide.
In March 2013, BiTime Inc. released LifeMap Discovery 1.1, a platform for discovery for stem therapy and biomedicines. The key component of LifeMap Discovery 1.1 is LifeMap Discovery, which integrates stem biology with cellsular, molecular, disease-related, and anatomical information and also has data mining capabilities.
In August 2015, International Stem cells Corporation (ISCC) announced the completion of clinical trial of its new compound, which it intends to use for the skin treatment. The new compound will be included in Lifeline Skin Care, Inc. to improve the skin elasticity and decrease skin roughness.
In March 2015, ISCC announced that it has received the patent approval for Japan to develop human stem bank from pathogenically activated eggs. This patent has made intellectual position of the company and its relationship with Japan stronger.
Avail customized purchase options to meet your research needs:
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.